Stocks · News reference

8-K filing — MetaVia Inc. (MTVA)

Sep 9, 2026, 1:00 PMSEC EDGAR

Filed: 2026-09-09 AccNo: 0001104659-26-106156 Size: 235 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

MTVA

Source: edgar
Observed: Sep 9, 2026, 1:00 PM
Checked: Sep 9, 2026, 1:00 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 9, 2026, 12:07 PMBenzinga Newsdesk
MetaVia Says Preclinical Tissue Distribution Study Showed Highest DA-1726 Exposure In Adipose Tissue And Prolonged Tissue Retention Through 144 Hours; Says 16-Week Topline Data Expected In Q4, 24-Week Results In Q1 2027
MTVA
BenzingaAug 6, 2026, 10:10 PMBenzinga Newsdesk
MetaVia Q2 EPS $(0.90) Misses $(0.82) Estimate
MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.82) by 9.76 percent. This is a 68.53 percent increase over losses of $(2.86) per share from the
MTVA
BenzingaJul 9, 2026, 12:36 PMBenzinga Newsdesk
MetaVia Says All Enrolled Active Patients In Part 3 Of Its Phase 1 Clinical Trial Evaluating DA-1726 For Obesity Treatment Completed Dose Titration, Now Receiving Highest Target Doses In Both Study Cohorts
MTVA

8-K filing — MetaVia Inc. (MTVA)

Connected Markets

Related Headlines

MetaVia Says Preclinical Tissue Distribution Study Showed Highest DA-1726 Exposure In Adipose Tissue And Prolonged Tissue Retention Through 144 Hours; Says 16-Week Topline Data Expected In Q4, 24-Week Results In Q1 2027

MetaVia Q2 EPS $(0.90) Misses $(0.82) Estimate

MetaVia Says All Enrolled Active Patients In Part 3 Of Its Phase 1 Clinical Trial Evaluating DA-1726 For Obesity Treatment Completed Dose Titration, Now Receiving Highest Target Doses In Both Study Cohorts